Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "spending"

67 News Found

Vyome Holdings bolsters financial position to support VT-1953 pivotal study through 2027
Biotech | April 02, 2026

Vyome Holdings bolsters financial position to support VT-1953 pivotal study through 2027

As of December 31, 2025, the company reported total cash, cash equivalents and short-term investments of approximately $4.94 million


Merck delivers resilient 2025 performance despite global headwinds
News | March 06, 2026

Merck delivers resilient 2025 performance despite global headwinds

Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results


PharmEasy integrates with Samsung Health to streamline digital healthcare
Digitisation | February 23, 2026

PharmEasy integrates with Samsung Health to streamline digital healthcare

Samsung Health users can now order medicines, book lab tests and online consultations through PharmEasy, along with 6 months of complimentary PharmEasy Plus membership


Mankind Pharma overhauls global supply chain with AI
Supply Chain | February 17, 2026

Mankind Pharma overhauls global supply chain with AI

The initiative, delivered in collaboration with Accenture, integrates digitally enabled operating models powered by advanced analytics and AI across the company’s procurement, manufacturing, and distribution networks


Eli Lilly posts blockbuster Q4 2025 results, issues bullish 2026 outlook
News | February 05, 2026

Eli Lilly posts blockbuster Q4 2025 results, issues bullish 2026 outlook

US revenue increased 43% to $12.9 billion, fueled by a 50% jump in volume, partially offset by a 7% decline in realized prices


InflaRx shifts focus to lead drug, cuts costs by 30% to extend cash runway
Biopharma | January 11, 2026

InflaRx shifts focus to lead drug, cuts costs by 30% to extend cash runway

InflaRx is streamlining operations and largely discontinuing non-essential activities outside izicopan’s development